Early is Good, founded in 2020 and based in Indianapolis, Indiana, is a medical organization dedicated to the early and accurate detection of renal system diseases. Utilizing a biomarker-based approach, the company aims to make disease detection widely accessible. Their core mission is to improve patient outcomes through early diagnosis, and their vision is to revolutionize the healthcare industry by providing innovative diagnostic solutions.
Notable figures associated with Early is Good include founder Dr. Thakshila Liyanage. The company has garnered significant support, including a seed round investment from Social Capital, led by Chamath Palihapitiya. Key achievements include a collaboration with the Mayo Clinic to develop a comprehensive liquid biopsy test for advanced prostate cancer and the introduction of BCDx, a breakthrough bladder cancer diagnosis test. Early is Good's impact lies in its potential to transform disease detection and improve patient care on a global scale.
